GET DAILY SIGNALSPhilip Morris International (PM): Path Toward the $220 Level
Key Takeaways
- The central $220 target represents the average of verified analyst price targets above the latest price, rounded for clarity.
- Shares closed recently near $197.88, implying roughly an 11% advance to reach that level.
- The broader analyst range spans about $175 to $235, with the overall average near $212, or about 7% above current levels.
- Key supports include accelerating smoke-free growth from IQOS and ZYN, steady cigarette pricing power, and a reliable dividend.
- Primary risks center on a premium valuation, currency fluctuations, and shifting nicotine regulations.
Analyst Views and Target Dispersion
More than a dozen sell-side firms follow PM, and the consensus leans constructive with a rating around Moderate Buy or Buy. Targets vary more than usual, however, from roughly $175 at Bernstein (Hold) to $235 at the high end, producing an arithmetic mean near $212. I calculated the $220 figure by averaging only those verified targets that sit above the current price, including Stifel at about $232, Barclays at $225, Goldman Sachs at $222, Argus at $220, Needham at $220, Morgan Stanley at $215, and Bank of America at $211. That exercise yields roughly $218, which rounds to the central target used here.
The spread highlights real differences in outlook. Bulls at firms such as Argus and Stifel cite strong IQOS and ZYN momentum and have raised targets following the third-quarter beat. More measured voices, including UBS at $201 (Neutral) and Bernstein at $175, focus on valuation, foreign-exchange pressures, and regulatory uncertainty. No single target serves as a guarantee.
Recent Price Action and the Road to $220
At the November 6, 2026 close, PM finished at $197.88 after pulling back from its 52-week high of $214.35 reached in late October. The shares remain well above the 52-week low near $146, with a market capitalization around $308 billion and a forward dividend yield of about 3.2%. An 11% move to $220 would mark a fresh all-time high. Recent results showed adjusted EPS beating estimates on continued double-digit smoke-free revenue growth, though guidance framed at or below the midpoint of prior expectations added some volatility.
Factors That Could Support Further Gains
- Smoke-free momentum. IQOS heated tobacco and ZYN nicotine pouches continue to drive growth, with ZYN securing U.S. FDA marketing authorization and smoke-free products now forming a sizable revenue share.
- Pricing strength. The core cigarette business, anchored by Marlboro internationally, generates reliable cash flow to support the dividend and investment in reduced-risk offerings.
- Earnings trajectory. Recent quarterly beats and upward revisions from analysts at Argus and Stifel reflect growing confidence in the outlook.
- Defensive qualities. As a consumer staples name with steady demand, PM often performs relatively well amid broader economic uncertainty.
Potential Headwinds to Monitor
- Valuation. The stock trades at a premium P/E relative to its history, which leaves limited margin if growth slows.
- Currency exposure. As a global operator, results remain sensitive to exchange-rate moves, and management has at times guided toward the lower half of expectations.
- Regulatory and competitive pressures. Nicotine-pouch competition, possible flavor restrictions in Europe, and excise-tax changes continue to warrant attention.
- Concentration risk. The thesis depends heavily on sustained smoke-free acceleration; any slowdown could pressure multiples.
Technical Context and Key Levels
Following the retreat from $214.35, the stock appears to be consolidating. The $180–$185 zone stands out as initial support, with a deeper buffer near $170–$175. On the upside, $205–$210 represents the first resistance band, followed by the prior high near $214 and then the $220 threshold, which sits just above the record and could serve as a meaningful breakout point. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Time Horizon and Items to Watch
Most analyst targets reflect a roughly 12-month horizon. Investors considering the path to $220 should track the next earnings release and full-year guidance, IQOS and ZYN shipment trends, FDA and international regulatory updates, currency moves, and any further target revisions. Dividend announcements and capital-allocation commentary will also matter for income-focused holders. From what I see, these elements together shape the near-term setup.
Using Tickeron AI Daily Buy/Sell Signals for Monitoring
In my view, Tickeron’s AI Daily Buy/Sell Signals provide a practical way to stay on top of names like PM that move between support and resistance. The tool applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on technical behavior and market shifts. I find it useful for spotting trend changes more efficiently while continuing with my own research and position reviews.
Overall Perspective
The $220 target averages the analyst projections currently above the recent close near $198 and equates to roughly an 11% advance. It remains a modest yet plausible objective just above the 52-week high. Strong smoke-free growth, pricing power in combustibles, and the dividend form the core supports, while valuation, currency sensitivity, and regulatory risks represent the main obstacles. The wide $175-to-$235 analyst range underscores genuine uncertainty, and no figure should be viewed as a forecast. Monitoring earnings, guidance, smoke-free shipments, and technical levels around $205–$214 offers the clearest picture of whether the stock can sustain a move toward that level.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PMI's RSI Oscillator recovers from overbought zone
The 10-day RSI Indicator for PMI moved out of overbought territory on October 20, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 3 instances where the indicator moved out of the overbought zone. In 3 of the 3 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for PMI turned negative on October 22, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 7 similar instances when the indicator turned negative. In 7 of the 7 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PMI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
PMI broke above its upper Bollinger Band on October 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 9 of 11 cases where PMI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Momentum Indicator moved above the 0 level on November 05, 2026. You may want to consider a long position or call options on PMI as a result. In 12 of 15 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
PMI moved above its 50-day moving average on November 05, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PMI crossed bullishly above the 50-day moving average on October 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 1 of 1 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +25.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where PMI advanced for three days, in 38 of 45 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 6 of 12 cases where PMI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 50%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. PMI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.266) is normal, around the industry mean (4.142). P/E Ratio (-0.251) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.114) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PMI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement